May 21, 2017Anavex Life Sciences Reports New Data for ANAVEX 2-73 in Neurodevelopmental DisordersAntiepileptic Drug Trials XIV 2017 Conference in Aventura, Florida on May 19th, 2017.View Presentation
Antiepileptic Drug Trials XIV 2017 Conference in Aventura, Florida on May 19th, 2017.View Presentation
New Phase IIb/III Clinical Data Demonstrates Over Three Years of Continuous Treatment with Oral Blarcamesine to Significantly Benefit Early Alzheimer’s Disease Patients
Anavex Life Sciences Reports Fiscal 2024 Fourth Quarter Financial Results and Provides Business Update
